Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.90)
# 264
Out of 4,534 analysts
740
Total ratings
53.5%
Success rate
23.9%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $745 → $739 | $535.69 | +37.95% | 62 | Jul 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $137 → $165 | $134.27 | +22.89% | 37 | Jul 17, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | n/a | $83.87 | - | 49 | Jul 7, 2026 | |
| DBVT DBV Technologies | Maintained: Buy | $55 | $14.57 | +277.49% | 45 | Jun 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $132 → $146 | $116.62 | +25.19% | 32 | Jun 15, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $35 → $12 | $7.16 | +67.60% | 21 | May 19, 2026 | |
| ALT Altimmune | Maintained: Buy | $14 → $11 | $2.81 | +291.46% | 81 | May 14, 2026 | |
| SPRB Spruce Biosciences | Maintained: Buy | $170 → $150 | $44.50 | +237.08% | 28 | May 14, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $12 → $11 | $3.05 | +260.66% | 2 | May 13, 2026 | |
| KLRS Kalaris Therapeutics | Maintained: Buy | $26 → $25 | $4.00 | +525.00% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $74 | $33.55 | +120.57% | 34 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $86 | $60.14 | +43.00% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 → $28 | $9.11 | +207.35% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $1.31 | +587.02% | 1 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $176 → $152 | $104.60 | +45.32% | 21 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.76 | +354.55% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $120 → $113 | $46.98 | +140.53% | 25 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $63 | $45.69 | +37.89% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.71 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $18.82 | - | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $11 | $5.49 | +100.36% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.83 | +369.97% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $4 | $0.6537 | +511.90% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.82 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.71 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $28.06 | n/a | 1 | May 12, 2023 |
Madrigal Pharmaceuticals
Jul 17, 2026
Maintained: Buy
Price Target: $745 → $739
Current: $535.69
Upside: +37.95%
Protagonist Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: $137 → $165
Current: $134.27
Upside: +22.89%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $83.87
Upside: -
DBV Technologies
Jun 30, 2026
Maintained: Buy
Price Target: $55
Current: $14.57
Upside: +277.49%
Mirum Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $132 → $146
Current: $116.62
Upside: +25.19%
Sagimet Biosciences
May 19, 2026
Maintained: Buy
Price Target: $35 → $12
Current: $7.16
Upside: +67.60%
Altimmune
May 14, 2026
Maintained: Buy
Price Target: $14 → $11
Current: $2.81
Upside: +291.46%
Spruce Biosciences
May 14, 2026
Maintained: Buy
Price Target: $170 → $150
Current: $44.50
Upside: +237.08%
Opus Genetics
May 13, 2026
Maintained: Buy
Price Target: $12 → $11
Current: $3.05
Upside: +260.66%
Kalaris Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $26 → $25
Current: $4.00
Upside: +525.00%
May 13, 2026
Maintained: Buy
Price Target: $52 → $74
Current: $33.55
Upside: +120.57%
May 12, 2026
Maintained: Buy
Price Target: $61 → $86
Current: $60.14
Upside: +43.00%
May 7, 2026
Maintained: Buy
Price Target: $25 → $28
Current: $9.11
Upside: +207.35%
May 5, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $1.31
Upside: +587.02%
Mar 17, 2026
Maintained: Buy
Price Target: $176 → $152
Current: $104.60
Upside: +45.32%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.76
Upside: +354.55%
Feb 27, 2026
Maintained: Buy
Price Target: $120 → $113
Current: $46.98
Upside: +140.53%
Feb 24, 2026
Initiated Coverage: Buy
Price Target: $63
Current: $45.69
Upside: +37.89%
Feb 17, 2026
Maintained: Buy
Price Target: n/a
Current: $8.71
Upside: -
Jan 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $18.82
Upside: -
Oct 23, 2025
Maintained: Buy
Price Target: $8 → $11
Current: $5.49
Upside: +100.36%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $3.83
Upside: +369.97%
Oct 6, 2025
Maintained: Buy
Price Target: $15 → $4
Current: $0.6537
Upside: +511.90%
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $6.82
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $16.71
Upside: n/a
May 12, 2023
Maintained: Buy
Price Target: $24
Current: $28.06
Upside: n/a